At Deutsche Telekom Laboratories we are investigating how group communication can be enhanced wit... more At Deutsche Telekom Laboratories we are investigating how group communication can be enhanced with contextual information such as reachability. We demonstrate these methods using a group communication scenario which is of interest to us from a user and telco perspective. The scenario includes features such as messaging, presence and “click-to” style communication, including conferencing between friends and persons with common interests. We summarize our analysis of two types of approaches to the next generation IMS platform capabilities, modular and layered approaches. We include lessons learned from our prototypes efforts, which made use of IMS capabilities. We point out some of the technical challenges that were confronted while realizing a showcase of use cases involving groups communication involving users using mobile devices and as well as users connected by web on their home PCs.
Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain ... more Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
At Deutsche Telekom Laboratories we are investigating how group communication can be enhanced wit... more At Deutsche Telekom Laboratories we are investigating how group communication can be enhanced with contextual information such as reachability. We demonstrate these methods using a group communication scenario which is of interest to us from a user and telco perspective. The scenario includes features such as messaging, presence and “click-to” style communication, including conferencing between friends and persons with common interests. We summarize our analysis of two types of approaches to the next generation IMS platform capabilities, modular and layered approaches. We include lessons learned from our prototypes efforts, which made use of IMS capabilities. We point out some of the technical challenges that were confronted while realizing a showcase of use cases involving groups communication involving users using mobile devices and as well as users connected by web on their home PCs.
Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain ... more Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.
Uploads
Papers by Zuzana Dobes